Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of elsubrutinib, upadacitinib, and their combination in moderately to severely active systemic lupus erythematosus
2019-000638-20Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of elsubrutinib and upadacitinib in systemic lupus erythematosus (SLE) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Achievement of SLE Responder Index-4 and steroid dose less than or equal to 10 mg prednisone equivalent once daily. Started Sep 2019; status: completed.
02
Drugs
elsubrutinibupadacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2019-000638-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000638-20.